

**Virginia Medicaid**  
**Pharmacy & Therapeutics Committee Meeting**  
Agenda  
600 East Broad Street – 7<sup>th</sup> Floor Conference Rooms  
Richmond, VA 23219  
**April 18, 2013 – 10 AM**

**Welcome and Comments**

**Cindi Jones, Agency Director**

**Call to Order**

**Chair**

**Drug Utilization Review (DUR) Board Report**

**Avtar Dhillon, M.D., DMAS DUR Board**

**Magellan Medicaid Administration Update**

**Debbie Moody, RPh, Clinical Manager**

**Approval of Minutes from October 18, 2012 Meeting**

**P&T Committee Members**

**PDL Management**

**P&T Committee Members**

- **Old Business**
  - Evaluation of Long-term Use of Long Acting Beta Agonist (LABAs) in Children
- **PDL Phase I – New Drug Review (*Therapeutic Class*)**
  - candesartan/hydrochlorothiazide (*ACE inhibitors + Diuretic Combinations*)
  - valsartan/hydrochlorothiazide (*Angiotensin Receptor Blockers + Diuretic Combinations*)
  - Aerospan HFA™ (*Inhaled Corticosteroid*)
  - fenofibrate, Juxtapid™ & Vascepa™ (*Lipotropics – other*)
  - sildenafil 20 mg Tab (*Phosphodiesterase 5 inhibitors for PAH*)
  - Ilevro™ (*Ophthalmic Anti-inflammatory*)
  - Giazio™ (*Ulcerative Colitis*)
  - Trospium ER (*Urinary Antispasmodic*)
- **PDL Phase II – Annual Review (*Therapeutic Class*)**
  - ***Analgesics***
    - Barbiturate & Non-salicylate Analgesics (*and combinations*)
    - Narcotics (*includes Long Acting, Short Acting, combinations, and Lozenges*)
    - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (*includes Cox-2 Inhibitors*)
    - Opioid Analgesics & Dependency
    - Topical Agents & Anesthetics
  - ***Antibiotics/Anti-infectives***
    - 2<sup>nd</sup> and 3<sup>rd</sup> Generation Cephalosporins
    - 2<sup>nd</sup> and 3<sup>rd</sup> Generation Quinolones (systemic)
    - Ketolides & Macrolides (Adult and Pediatric)
    - Oral Antifungals
    - Otic Quinolones
    - Topical Antibiotics
  - ***Antivirals***
    - Antivirals for the treatment of Herpes or Influenza
    - Topical Antivirals
- **PDL Phase II – Annual Review (*continued*)**

- ***Bone Resorption Suppression and Related Agents***
  - Bisphosphonates
  - Calcitonins
  - Others
- ***Cardiac Medications***
  - Anticoagulants (*includes Low Molecular Weight Heparins, Factor XA Inhibitors and Oral Anticoagulants*)
  - Platelet Inhibitors
- ***Central Nervous System***
  - Antihyperkinesia/CNS Stimulants
  - Antimigraine
  - Non-Ergot Dopamine Receptor Agonists
  - Skeletal Muscle Relaxants
  - Smoking Cessation
- ***Dermatologic***
  - Acne Agents (*includes Benzoyl Peroxide, Clindamycin, Topical Retinoids & Combinations*)
  - Topical Agents For Psoriasis
- ***Endocrine and Metabolic Agents***
  - Androgenic Agents
  - Antihyperuricemics
  - Contraceptives (*Oral, Vaginal & Transdermal*)
  - Erythropoiesis Stimulating Proteins
  - Injectable Hypoglycemics (*includes Insulins, Incretin Mimetics, GLP-1 Receptor Agonists*)
  - Oral Hypoglycemics (*includes 2<sup>nd</sup> Generation Sulfonylureas, Alpha-Glucosidase Inhibitors, Biguanides, Biguanide combinations, Meglitinides, Thiazolidinediones, DPP-IV Inhibitors and Combinations*)
  - Progestational Agents
  - Vaginal Estrogens
- ***Gastrointestinal***
  - Motility Agents – GI Stimulants
- ***Immunologic Agents***
  - Multiple Sclerosis Agents
  - Self Administered Drugs for Rheumatoid Arthritis
- ***Ophthalmics*** (*moving to the fall meeting 10/13, not part of this review*)
  - Ophthalmic Glaucoma Agents (*includes Alpha-2 Adrenergic, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors*)
  - Ophthalmic Anti-Inflammatory Agents
  - Ophthalmic Antibiotics (*includes Quinolones & Macrolides*)
  - Allergic Conjunctivitis (*includes Ophthalmic Antihistamines & Mast Cell Stabilizers*)
- ***Respiratory*** (*moving to the fall meeting 10/13, not part of this review*)
  - Cough & Cold (*includes 1st Generation Antihistamines, Antihistamines & Expectorant combination, Expectorants, Narcotic Antitussive & Decongestant combinations, Narcotic Antitussive & Expectorant combinations, Non-narcotic Antitussive & Decongestant combinations, Non-narcotic Antitussive, 1st Generation Antihistamine & Decongestant combinations*)
  - Leukotriene Formation Inhibitors and Modifiers

Criteria Discussion of Phase I New Drugs

P&T Committee Members

Criteria Discussion of Phase II New Drugs

P&T Committee Members

Next Meet – October 17, 2013 (tentative)

Chair

**Oral Presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase II which are scheduled for review at the April meeting and new drugs in PDL Phase I listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase II Annual Review – April 2012 to present
- New Drugs in PDL Phase I Drug Classes – April 2011 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) and [dfmoody@magellanhealth.com](mailto:dfmoody@magellanhealth.com) by 5 p.m. EST on **Friday, March 22, 2013.**